Boston, MA 02/13/2014 (wallstreetpr) – Genetic Technologies Limited (ADR) (NASDAQ:GENE) had some good news waiting for it, from the United States Patent and Trademark Office, on Feb 10, 2014. The Apex patent organization in the country issued Genetic Technologies Limited (ADR) owned patent bearing -Patent No. 5,612,179 (the ‘179 patent) an ExParte re-examination certificate.
Merial LLC places request for third party re-examination
For Genetic Technologies Limited (ADR) (NASDAQ:GENE) Patent NO.179 is a key patent and was subjected to additional third party re-examination by Merial LLC located in Duluth, Georgia. The company’s specific request was of claims- 1-15, 17, 18, 26-29 and 32 of GENE patent. The claim and re-examination request was placed before USPTO on September 30, 2013.
Triumphant Genetic Technologies Limited (ADR) (NASDAQ:GENE) acting Chief Executive Officer Tom Howitt, announced that the new certificate is issued after the fourth successful resolution of the patent.
Genetic Technologies Limited (ADR) (NASDAQ:GENE) which has over two decades of services in the genetic testing niche, using non-coding DNA as well as other product patents. It has been an effective player in bringing the genetic testing on a commercial basis and operates from two epicentres- US as well as Australian trading exchanges.
The re-examination established the fact that GENE had a strong non-coding patent portfolio.
For GENE the new certificate is also important for it will now allow it to rework license settlement with such of the licensees, who have dues pending.
For GENE, the model of operation is the active out-licensing program, hence with the certificate settlements due need to be cleared.
Genetic Technologies Limited (ADR) (NASDAQ:GENE) has always remained focused on the expansion of the Oncology diagnostic asset management programs. In the US the main line of work is handled by its subsidiary Phenogen Science Inc. The novelty of this firm is the hugely predictive testing as well as assessment tools for detecting women related diseases.
